Recro Pharma Inc (NASDAQ:REPH) – Analysts at Piper Jaffray Companies raised their Q1 2019 earnings estimates for Recro Pharma in a report released on Sunday, March 24th. Piper Jaffray Companies analyst D. Amsellem now anticipates that the specialty pharmaceutical company will earn ($0.88) per share for the quarter, up from their prior forecast of ($0.90). Piper Jaffray Companies also issued estimates for Recro Pharma’s Q2 2019 earnings at ($0.74) EPS, Q3 2019 earnings at ($0.52) EPS, Q4 2019 earnings at ($0.51) EPS, FY2019 earnings at ($2.66) EPS, Q1 2020 earnings at ($0.47) EPS, Q2 2020 earnings at ($0.42) EPS, Q3 2020 earnings at ($0.52) EPS, Q4 2020 earnings at ($0.44) EPS, FY2020 earnings at ($1.84) EPS, FY2021 earnings at ($2.04) EPS, FY2022 earnings at ($0.86) EPS and FY2023 earnings at $0.62 EPS.

Other equities analysts have also recently issued research reports about the company. Oppenheimer set a $18.00 price target on Recro Pharma and gave the company a “buy” rating in a report on Wednesday, February 20th. Janney Montgomery Scott reiterated a “buy” rating and set a $13.00 price target on shares of Recro Pharma in a report on Thursday, January 31st. Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $9.25 price target for the company in a report on Wednesday, January 9th. ValuEngine lowered Recro Pharma from a “buy” rating to a “hold” rating in a report on Monday, December 3rd. Finally, Roth Capital reiterated a “neutral” rating and set a $7.50 price target (down from $15.00) on shares of Recro Pharma in a report on Monday. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $9.75.

NASDAQ:REPH opened at $6.05 on Wednesday. The company has a debt-to-equity ratio of 4.04, a quick ratio of 2.08 and a current ratio of 2.45. Recro Pharma has a fifty-two week low of $4.78 and a fifty-two week high of $13.05. The stock has a market cap of $136.78 million, a price-to-earnings ratio of -2.43 and a beta of -0.30.

Recro Pharma (NASDAQ:REPH) last released its earnings results on Tuesday, February 19th. The specialty pharmaceutical company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.17. Recro Pharma had a negative return on equity of 472.58% and a negative net margin of 103.07%. The company had revenue of $17.78 million for the quarter, compared to analysts’ expectations of $16.01 million.

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Recro Pharma by 5.7% during the 4th quarter. BlackRock Inc. now owns 1,154,815 shares of the specialty pharmaceutical company’s stock valued at $8,199,000 after buying an additional 62,787 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Recro Pharma by 26.0% during the 3rd quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock valued at $3,416,000 after buying an additional 99,200 shares during the last quarter. Engine Capital Management LP lifted its holdings in shares of Recro Pharma by 21.0% during the 3rd quarter. Engine Capital Management LP now owns 473,484 shares of the specialty pharmaceutical company’s stock valued at $3,366,000 after buying an additional 82,177 shares during the last quarter. Essex Investment Management Co. LLC lifted its holdings in shares of Recro Pharma by 1.9% during the 4th quarter. Essex Investment Management Co. LLC now owns 257,707 shares of the specialty pharmaceutical company’s stock valued at $1,830,000 after buying an additional 4,833 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Recro Pharma by 28.0% during the 2nd quarter. Northern Trust Corp now owns 220,965 shares of the specialty pharmaceutical company’s stock valued at $1,109,000 after buying an additional 48,297 shares during the last quarter. Institutional investors and hedge funds own 55.47% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Recommended Story: Moving Average (MA)

Earnings History and Estimates for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.